– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ende ...

Financial Performance and Guidance - Collegium reported 2024 sales of $631 million and expects 2025 sales to reach $743 million, representing an +18% increase[16] - The company anticipates 2025 net product revenues in the range of $735 million to $750 million, reflecting an +18% year-over-year growth[22] - Adjusted EBITDA for 2025 is projected to be between $435 million and $450 million, a +10% increase[22] - Adjusted operating expenses for 2025 are expected to be in the range of $220 million to $230 million, a +49% increase[22] Product Portfolio and Market Position - Jornay PM net revenue is expected to exceed $135 million in 2025, representing a +>34% increase from $100.7 million in 2024[40] - The pain portfolio experienced a +5% revenue growth in 2024, while total revenue grew +11%[20] - Q1 2025 pain portfolio product revenues reached $177.8 million, a +23% increase compared to $144.9 million in Q1 2024[32] - Jornay PM prescriptions grew +24% year-over-year in Q1 2025[32] Capital Allocation and Shareholder Value - Collegium initiated a $25 million Accelerated Share Repurchase (ASR) program in May 2025[33] - The company repurchased $222 million worth of shares between 2021 and 2025[47] Debt and Cash Flow - The company had approximately $200 million in cash and marketable securities at the end of Q1 2025[27] - Net debt to adjusted EBITDA stood at approximately 1.5x at the end of Q1 2025[33]